Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase III, Phase II/III and Phase II trial results, estimated CHMP supplemental filing results, and an expected patent expiration.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 2.4%, and the average probability a drug advances from Phase III is 14.3%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 43 licensing and asset acquisition deals involving pancreatic cancer drugs during 2015–20. The $1,240m global strategic collaboration agreement signed in 2016 between Novartis and Surface Oncology to develop immunotherapeutics targeting the tumor microenvironment and the interface of innate and adaptive immunity was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer therapeutics market is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 98 trials.
- Bristol-Myers Squibb leads industry sponsors with the highest number of clinical trials for pancreatic cancer, followed by Roche.
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
9 Subtypes
11 TREATMENT
11 Surgery
11 Ablation or embolization
12 Radiation therapy
12 Chemotherapy
12 Targeted therapy
13 Immunotherapy
13 Drugs used specifically for the treatment of PNETs
14 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
37 RECENT EVENTS AND ANALYST OPINION
37 Lynparza for Pancreatic Cancer (December 17, 2019)
37 Pegilodecakin for Pancreatic Cancer (October 16, 2019)
39 Acelarin for Pancreatic Cancer (August 20, 2019)
40 Mavorixafor for Pancreatic Cancer (July 17, 2019)
41 Napabucasin for Pancreatic Cancer (July 1, 2019)
42 Abraxane for Pancreatic Cancer (June 2, 2019)
42 Lynparza for Pancreatic Cancer (June 2, 2019)
44 NanoKnife System for Pancreatic Cancer (May 13, 2019)
45 MVT-5873 for Pancreatic Cancer (May 8, 2019)
46 Sacituzumab Govitecan for Pancreatic Cancer (April 29, 2019)
47 RX-3117 for Pancreatic Cancer (April 16, 2019)
48 Abraxane for Pancreatic Cancer (March 12, 2019)
50 Abraxane for Pancreatic Cancer (February 27, 2019)
51 BRACAnalysis Companion Diagnostic for Pancreatic Cancer (February 26, 2019)
52 Lynparza for Pancreatic Cancer (February 26, 2019)
53 SM-88 for Pancreatic Cancer (January 18, 2019)
54 Xuriden for Pancreatic Cancer (November 20, 2018)
56 Motixafortide for Pancreatic Cancer (October 19, 2018)
58 SpaceOAR System for Pancreatic Cancer (September 6, 2018)
60 KEY UPCOMING EVENTS
61 KEY REGULATORY EVENTS
61 Lynparza Gets US OK For Pancreatic Cancer
62 PROBABILITY OF SUCCESS
63 LICENSING AND ASSET ACQUISITION DEALS
63 Tyme, Eagle Collaborate On Development Of Pancreatic Cancer Drug
63 Astellas Taps Pandion In Pancreas Immunomodulator Deal
64 Novartis Snaps Up KRAS Inhibitor R&D
64 Deals Shaping The Medical Industry, October 2019
64 Spherix Gets Cancer IP From Kentucky, Maryland-Baltimore Universities
65 Tonix Signs Second License This Year With Columbia
65 Boehringer Ingelheim Snaps Up Lupin’s MEK Inhibitor For Difficult-To-Treat Cancers
65 Deals Shaping The Medical Industry, August 2019
66 Ono Licenses Rafael’s Novel Chemo-Sensitizing Agent For Asia
66 Mateon, Oncotelic Merge With Focus On Brain, Pancreatic Cancer Candidate
66 BioSense Picks Up Greater China Rights To Rexahn’s Cancer Candidate
68 PARENT PATENTS
70 REVENUE OPPORTUNITY
71 CLINICAL TRIAL LANDSCAPE
72 Sponsors by status
73 Sponsors by phase
74 Recent events
76 BIBLIOGRAPHY
76 Prescription information
78 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in incident cases of pancreatic cancer, 2017–26
20 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
20 Figure 3: Pipeline drugs for pancreatic cancer, by company
21 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
21 Figure 5: Pipeline drugs for pancreatic cancer, by classification
39 Figure 6: Pegilodecakin for Pancreatic Cancer (October 16, 2019): Phase III – SEQUOIA (w/FOLFOX)
44 Figure 7: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III – POLO
50 Figure 8: Abraxane for Pancreatic Cancer (March 12, 2019): Phase III – APACT – w/Gemcitabine (Adjuvant)
53 Figure 9: Lynparza for Pancreatic Cancer (February 26, 2019): Phase III – POLO
54 Figure 10: SM-88 for Pancreatic Cancer (January 18, 2019): Phase II – Tyme-88-Panc (>1L)
58 Figure 11: Motixafortide for Pancreatic Cancer (October 19, 2018): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
60 Figure 12: Key upcoming events in pancreatic cancer
62 Figure 13: Probability of success in the pancreatic cancer pipeline
63 Figure 14: Licensing and asset acquisition deals in pancreatic cancer, 2015–20
68 Figure 15: Parent patents in pancreatic cancer, 2020–25
69 Figure 16: Parent patents in pancreatic cancer, 2025–29
69 Figure 17: Parent patents in pancreatic cancer, 2029–38
71 Figure 18: Clinical trials in pancreatic cancer
71 Figure 19: Top 10 drugs for clinical trials in pancreatic cancer
72 Figure 20: Top 10 companies for clinical trials in pancreatic cancer
72 Figure 21: Trial locations in pancreatic cancer
73 Figure 22: Pancreatic cancer trials status
74 Figure 23: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
15 Table 1: Incident cases of pancreatic cancer, 2017–26
18 Table 2: Marketed drugs for pancreatic cancer
23 Table 3: Pipeline drugs for pancreatic cancer in the US
37 Table 4: Lynparza for Pancreatic Cancer (December 17, 2019)
38 Table 5: Pegilodecakin for Pancreatic Cancer (October 16, 2019)
39 Table 6: Acelarin for Pancreatic Cancer (August 20, 2019)
40 Table 7: Mavorixafor for Pancreatic Cancer (July 17, 2019)
41 Table 8: Napabucasin for Pancreatic Cancer (July 1, 2019)
42 Table 9: Abraxane for Pancreatic Cancer (June 2, 2019)
43 Table 10: Lynparza for Pancreatic Cancer (June 2, 2019)
45 Table 11: NanoKnife System for Pancreatic Cancer (May 13, 2019)
46 Table 12: MVT-5873 for Pancreatic Cancer (May 8, 2019)
47 Table 13: Sacituzumab Govitecan for Pancreatic Cancer (April 29, 2019)
48 Table 14: RX-3117 for Pancreatic Cancer (April 16, 2019)
49 Table 15: Abraxane for Pancreatic Cancer (March 12, 2019)
50 Table 16: Abraxane for Pancreatic Cancer (February 27, 2019)
51 Table 17: BRACAnalysis Companion Diagnostic for Pancreatic Cancer (February 26, 2019)
52 Table 18: Lynparza for Pancreatic Cancer (February 26, 2019)
53 Table 19: SM-88 for Pancreatic Cancer (January 18, 2019)
55 Table 20: Xuriden for Pancreatic Cancer (November 20, 2018)
57 Table 21: BL-8040 for Pancreatic Cancer (October 19, 2018)
58 Table 22: SpaceOAR System for Pancreatic Cancer (September 6, 2018)
70 Table 23: Historical global sales, by drug ($m), 2014–18
70 Table 24: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Transcatheter Embolization and Occlusion Devices 
Sign up to the